2. Signaling Pathways
  3. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  4. EGFR
  5. EGFR Ligand

EGFR Ligand

EGFR Isoform Comparison

EGFR Ligands (13):

Cat. No. Product Name Effect Purity
  • HY-N2524
    Camelliaside A
    		Ligand 99.65%
    Camelliaside A is a phytochemical and also a HER2 ligand. Camelliaside A shows no inhibitory effect on mycelial growth of Rhizoctonia solani, indicating no antifungal activity against this pathogen. Camelliaside A is applicable to breast cancer-related research.
  • HY-W714853
    (+)-Theta-cypermethrin
    		Ligand
    (+)-Theta-cypermethrin is a stereoisomer of Cypermethrin (HY-B0829) that possesses blood-brain barrier penetration ability and binds to AKT1, SRC, STAT3 and EGFR with high affinity. (+)-Theta-cypermethrin reduces the amplitude of delayed rectifier potassium channel currents, shifts the steady-state activation curve to negative potentials, and shifts the steady-state inactivation curve to negative potentials at higher concentrations. (+)-Theta-cypermethrin induces abnormal electrical activity in rat hippocampal neurons. (+)-Theta-cypermethrin causes chronic respiratory system damage and exhibits neurotoxicity.
  • HY-P11590
    WGYRGFYC
    		Ligand
    WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a KD of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer.
  • HY-178311
    EGFR Ligand-Linker Conjugates 4
    		Ligand
    EGFR Ligand-Linker Conjugates 4 is a conjugate of the EGFR ligand (HY-178313) and the linker. EGFR Ligand-Linker Conjugates 4 can be used for synthesizing PROTAC EGFR degrader 16 (HY-178242).
  • HY-P11760
    HER2-targeted peptide H10
    		Ligand
    HER2-targeted peptide H10 is a HER2-targeting peptide with a Kd value of 30.4 nM. HER2-targeted peptide H10 specifically accumulates in HER2-positive tumor tissues of xenograft mice, when conjugated with nanoparticles. HER2-targeted peptide H10 can be used for studies related to HER2-positive breast cancer.
  • HY-P11613
    DOTA-WC8
    		Ligand
    DOTA-WC8 is a HER2-targeting peptide probe with a KD of 61.20 nM. 68Ga-labeled DOTA-WC8 serves as a PET imaging agent for the specific identification of HER2-positive breast cancer. DOTA-WC8 is applicable to breast cancer-related research.
  • HY-183253
    DL149
    		Ligand
    DL149 is a component of an antibody-drug conjugate (ADC) formed by conjugating the eIF4A inhibitor FD236 (HY-186186) with an ADC linker, and exhibits potential antitumor activity. DL149 can bind to an anti-HER2 antibody to form a complete ADC molecule, which precisely binds to the HER2 receptor on the surface of tumor cells. After internalization into cells, it releases the eIF4A inhibitor payload. DL149 irreversibly blocks the mRNA translation process in tumor cells, thereby inhibiting tumor cell proliferation and inducing their death. DL149 exhibits in vivo antitumor activity in the SK-OV-3 xenograft tumor model, and can be used for the research of HER2-positive solid tumors.
  • HY-160087
    SG3376
    		Ligand
    SG3376 is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). SG3376 is promising for research of HER2-overexpressing cancers (e.g., breast, gastric cancer).
  • HY-P11752
    Cyclo(KLARLLT)
    		Ligand
    Cyclo (KLARLLT) is an EGFR ligand with a Kd value of 1.16 μM. Cyclo (KLARLLT) binds to domain I of EGFR and interacts with both the open and closed conformations of EGFR. Cyclo (KLARLLT) is a modified variant of LARLLT (HY-P11078). Cyclo (KLARLLT) can be used in the research of colorectal cancer.
  • HY-P10792A
    HYNIC-H6F
    		Ligand
    HYNIC-H6F is a SPECT imaging probe with binding specificity for human epidermal growth factor receptor 2 (HER2) domain II (IC50 = 11 nM). HYNIC-H6F accumulates in HER2-positive breast cancer xenografts via receptor-mediated uptake, while shows low uptake in HER2-negative breast cancer xenografts. HYNIC-H6F enables non-invasive detection of HER2-positive breast cancer in mouse models and allows evaluation of HER2 expression levels without blocking interference. HYNIC-H6F can be used in breast cancer-related research.
  • HY-P11757
    Cyclo[K(N3)larllt]
    		Ligand
    Cyclo[K(N3)larllt] is a seven-membered cyclic peptide targeting EGFR, with a Kd value of 5.09 μM, and exhibits binding selectivity toward homologous proteins HER2 and HER3. Cyclo[K(N3)larllt] has no cytotoxicity and shows no growth inhibitory effect on cancer cells overexpressing EGFR. Cyclo[K(N3)larllt] can serve as a ligand for EGFR-targeted fluorescent conjugates, which is applicable to the detection of cancers with EGFR overexpression. Cyclo[K(N3)larllt] can be used in the research of colorectal cancer.
  • HY-P11761
    HYNIC-H10F
    		Ligand
    HYNIC-H10F is a conjugate of HER2-targeting peptide H10F and bifunctional chelator HYNIC. HYNIC-H10F can be used in breast cancer-related research.
  • HY-180480
    NSC 104999
    		Ligand
    NSC 104999 is a Grb7 SH2 domain binder with moderate affinity (Kd = 32.3 μM). NSC 104999 exhibits anticancer activity against breast cancer.